US · EW
Edwards Lifesciences Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Irvine, CA 92614
- Website
- edwards.com
Price · as of 2025-12-31
$83.98
Market cap 50.77B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $80.93 | -3.63% |
| Intrinsic Value(DCF) | $39.22 | -53.3% |
| Graham-Dodd Method(GD) | $23.83 | -71.62% |
| Graham Formula(GF) | $35.29 | -57.97% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $11.49 | $40.97 | $2.59 | $3.16 | $8.07 |
| 2012 | $15.05 | $39.82 | $5.53 | $3.71 | $8.83 |
| 2013 | $12.01 | $36.94 | $4.93 | $4.67 | $9.00 |
| 2014 | $22.56 | $45.40 | $7.94 | $9.19 | $26.83 |
| 2015 | $29.21 | $45.85 | $7.77 | $6.73 | $11.64 |
| 2016 | $30.91 | $49.16 | $25.33 | $7.58 | $23.27 |
| 2017 | $46.44 | $53.78 | $34.90 | $7.87 | $23.04 |
| 2018 | $56.42 | $58.55 | $26.28 | $8.98 | $18.60 |
| 2019 | $68.62 | $67.15 | $27.49 | $13.15 | $40.54 |
| 2020 | $82.07 | $69.01 | $10.32 | $12.07 | $11.77 |
| 2021 | $103.45 | $84.67 | $25.49 | $19.55 | $63.90 |
| 2022 | $74.34 | $70.85 | $12.03 | $19.79 | $26.57 |
| 2023 | $92.14 | $76.36 | $5.28 | $20.63 | $3.32 |
| 2024 | $70.33 | $90.73 | $7.61 | $48.68 | $114.24 |
| 2025 | $87.18 | $80.93 | $6.72 | $23.83 | $35.29 |
AI valuation
Our deep-learning model estimates Edwards Lifesciences Corporation's (EW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $80.93
- Current price
- $83.98
- AI upside
- -3.63%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$39.22
-53.3% upside
Graham-Dodd
$23.83
-71.62% upside
Graham Formula
$35.29
-57.97% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EW | Edwards Lifesciences Corp… | $83.98 | 50.77B | -4% | -53% | -72% | -58% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| BRKR | Bruker Corporation | $40.11 | 6.09B | -2% | -60% | -66% | — | 206.96 | 2.44 | 1.76 | 17.43 | — | -7.46 | 45.61% | 6.30% | -0.25% | 1.37% | 2.20% | 0.48% | 0.76 | 4.69 | 1.73 | 0.66 | 3.59 | -11974.00% | 208.00% | -6816.00% | 0.72% | 0.10 | 1.10% | 0.38% | 78.10% | 8.68% | 35.15 | 175.83 | 2.22 | 1.82 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| DXCM | DexCom, Inc. | $73.43 | 28.64B | +15% | -6% | -76% | -33% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| VEEV | Veeva Systems Inc. | $182.01 | 29.92B | +3% | +13% | -70% | -43% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
- CEO
- Bernard J. Zovighian
- Employees
- 15.8K
- Beta
- 0.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($39.22 ÷ $83.98) − 1 = -53.3% (DCF, example).